Suppr超能文献

多层次分析辅导员对在物质滥用治疗中使用丁丙诺啡的态度。

A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

机构信息

Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR 97239, USA.

出版信息

J Subst Abuse Treat. 2011 Dec;41(4):374-85. doi: 10.1016/j.jsat.2011.05.005. Epub 2011 Aug 6.

Abstract

Despite evidence that buprenorphine is effective and safe and offers greater access as compared with methadone, implementation for treatment of opiate dependence continues to be weak. Research indicates that legal and regulatory factors, state policies, and organizational and provider variables affect adoption of buprenorphine. This study uses hierarchical linear modeling to examine National Treatment Center Study data to identify counselor characteristics (attitudes, training, and beliefs) and organizational factors (accreditation, caseload, access to buprenorphine, and other evidence-based practices) that influence implementation of buprenorphine for treatment of opiate dependence. Analyses showed that provider training about buprenorphine, higher prevalence of opiate-dependent clients, and less treatment program emphasis on a 12-step model predicted greater counselor acceptance and perceived effectiveness of buprenorphine. Results also indicate that program use of buprenorphine for any treatment purpose (detoxification, maintenance, and/or pain management) and time (calendar year in data collection) was associated with increased diffusion of knowledge about buprenorphine among counselors and with more favorable counselor attitudes toward buprenorphine.

摘要

尽管有证据表明丁丙诺啡有效且安全,并且与美沙酮相比,获得它的途径更多,但阿片类药物依赖的治疗实施仍然很薄弱。研究表明,法律和监管因素、州政策以及组织和提供者变量会影响丁丙诺啡的采用。本研究使用层次线性模型来检验国家治疗中心研究的数据,以确定影响丁丙诺啡用于治疗阿片类药物依赖的实施的咨询师特征(态度、培训和信念)和组织因素(认证、病例量、丁丙诺啡的可及性和其他基于证据的实践)。分析表明,关于丁丙诺啡的培训、阿片类药物依赖患者的更高患病率以及治疗计划对 12 步模型的重视程度较低,这预示着咨询师对丁丙诺啡的接受程度和对其有效性的看法更高。结果还表明,治疗计划将丁丙诺啡用于任何治疗目的(解毒、维持和/或疼痛管理)和时间(数据收集的日历年)与咨询师对丁丙诺啡的了解的传播增加以及对丁丙诺啡的更有利的态度有关。

相似文献

1
A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.
J Subst Abuse Treat. 2011 Dec;41(4):374-85. doi: 10.1016/j.jsat.2011.05.005. Epub 2011 Aug 6.
2
Counselor training and attitudes toward pharmacotherapies for opioid use disorder.
Subst Abus. 2016;37(1):47-53. doi: 10.1080/08897077.2015.1062457. Epub 2015 Jul 13.
3
Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.
Addict Behav. 2014 May;39(5):889-96. doi: 10.1016/j.addbeh.2014.01.016. Epub 2014 Feb 7.
4
Buprenorphine diffusion: the attitudes of substance abuse treatment counselors.
J Subst Abuse Treat. 2005 Sep;29(2):95-106. doi: 10.1016/j.jsat.2005.05.002.
5
7
Client and counselor attitudes toward the use of medications for treatment of opioid dependence.
J Subst Abuse Treat. 2007 Mar;32(2):207-15. doi: 10.1016/j.jsat.2006.09.002. Epub 2006 Dec 8.
8
Attitudes toward buprenorphine and methadone among opioid-dependent individuals.
Am J Addict. 2008 Sep-Oct;17(5):396-401. doi: 10.1080/10550490802268835.
9
Use and misuse of opioid replacement therapies: a Queensland study.
Subst Use Misuse. 2012 Jan;47(1):78-85. doi: 10.3109/10826084.2011.629017.
10
Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
J Subst Abuse Treat. 2009 Jul;37(1):95-100. doi: 10.1016/j.jsat.2008.09.007. Epub 2008 Nov 11.

引用本文的文献

1
Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone.
Drug Alcohol Depend Rep. 2023 Feb 7;6:100138. doi: 10.1016/j.dadr.2023.100138. eCollection 2023 Mar.
2
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
Front Psychol. 2021 Mar 15;12:645246. doi: 10.3389/fpsyg.2021.645246. eCollection 2021.
4
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.
Neurotherapeutics. 2020 Jan;17(1):55-69. doi: 10.1007/s13311-019-00814-4.
5
Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.
J Behav Health Serv Res. 2019 Jan;46(1):151-163. doi: 10.1007/s11414-018-9629-4.
6
Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives.
Addict Behav. 2018 Nov;86:111-117. doi: 10.1016/j.addbeh.2018.05.017. Epub 2018 May 23.

本文引用的文献

2
Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S68-75. doi: 10.1097/QAI.0b013e31820a8226.
3
Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S62-7. doi: 10.1097/QAI.0b013e31820a820f.
4
Advancing performance measures for use of medications in substance abuse treatment.
J Subst Abuse Treat. 2011 Jan;40(1):35-43. doi: 10.1016/j.jsat.2010.08.005. Epub 2010 Oct 8.
5
Accountability measures--using measurement to promote quality improvement.
N Engl J Med. 2010 Aug 12;363(7):683-8. doi: 10.1056/NEJMsb1002320. Epub 2010 Jun 23.
6
The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.
J Gen Intern Med. 2010 Sep;25(9):936-41. doi: 10.1007/s11606-010-1377-y. Epub 2010 May 11.
7
Non-medical use of prescription analgesics: a three-year national longitudinal study.
J Addict Dis. 2009 Jul;28(3):232-42. doi: 10.1080/10550880903028452.
9
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
J Subst Abuse Treat. 2009 Oct;37(3):307-12. doi: 10.1016/j.jsat.2008.12.004. Epub 2009 Jul 3.
10
Counselor attitudes toward pharmacotherapies for alcohol dependence.
J Stud Alcohol Drugs. 2009 Jul;70(4):628-35. doi: 10.15288/jsad.2009.70.628.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验